Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nuvo Pennsaid Mid-2006 Filing Planned Following Positive Phase III Results

This article was originally published in The Pink Sheet Daily

Executive Summary

The trial of the topical osteoarthritis therapy was designed to address questions raised in FDA’s August 2002 “not approvable” letter, Nuvo says.

You may also be interested in...



Nuvo’s Pennsaid Resubmission Delayed Again

Firm now projects a potential mid-2009 approval for the topical NSAID for osteoarthritis.

Nuvo’s Pennsaid Resubmission Delayed Again

Firm now projects a potential mid-2009 approval for the topical NSAID for osteoarthritis.

Pennsaid Amended NDA Has Mid-December User Fee Date

Nuvo’s Class 2 resubmission includes data from a Phase III efficacy trial and single-arm, long-term safety study.

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel